0000899243-23-010715.txt : 20230405 0000899243-23-010715.hdr.sgml : 20230405 20230405161514 ACCESSION NUMBER: 0000899243-23-010715 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230403 FILED AS OF DATE: 20230405 DATE AS OF CHANGE: 20230405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brennan Aoife CENTRAL INDEX KEY: 0001714563 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37566 FILM NUMBER: 23802713 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET, SUITE 320 STREET 2: C/O SYNLOGIC, INC. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNLOGIC, INC. CENTRAL INDEX KEY: 0001527599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261824804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-401-9975 MAIL ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Mirna Therapeutics, Inc. DATE OF NAME CHANGE: 20110809 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-03 0 0001527599 SYNLOGIC, INC. SYBX 0001714563 Brennan Aoife C/O SYNLOGIC, INC. 301 BINNEY STREET, SUITE 402 CAMBRIDGE MA 02142 1 1 0 0 See Remarks 1 Common Stock 2023-04-03 4 S 0 19042 0.5758 D 256301 D Represents the number of shares sold by the reporting person on April 3, 2023 to cover the tax liability in connection with the vesting of three restricted stock awards, vesting on April 1, 2023, that were granted in 2020, 2021, and 2022. The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5750 to $0.5798, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. President and Chief Executive Officer /s/ Aoife Brennan 2023-04-05